Enhanced in vivo uptake of glucocerebrosidase
US5549892A · kind A · utility
54Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 1993 |
| Grant date | Aug 27, 1996 |
| Priority date | — |
| Expiry date | Jun 21, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/44
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A pharmaceutical composition comprising remodelled recombinant glucocerebrosidase (GCR) is described that provides a therapeutic effect at doses that are lower then those required using remodelled naturally occurring GCR. A method of treating patients with Gaucher's disease using remodelled recombinant GCR is also provided. In vivo uptake of exogenous molecules can be determined by extracting a mixture of cells from a subject, enriching the target cells in vitro, lysing the cells and determining the amount of exogenous molecules.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.